Cardiovascular Risk and Health Among People With Human Immunodeficiency Virus (HIV) Eligible for Primary Prevention: Insights From the REPRIEVE Trial is a research paper published in Clinical Infectious Diseases (2021). On theSindex it has a DataRank of 0. It has been cited 40 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Heart, Lung, and Blood Institute
Grant: 5K24HL113128
National Heart, Lung, and Blood Institute
Grant: 5T32HL076136
National Heart, Lung, and Blood Institute
Grant: HL137562
National Heart, Lung, and Blood Institute
Grant: HL146199
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI068636
National Institute of Allergy and Infectious Diseases
Grant: UM1 AI106701
National Institute of Allergy and Infectious Diseases
Grant: P30 DK 040561
National Institute of Allergy and Infectious Diseases
Grant: R01 MD013493
Oregon Health and Science University
Grant: 13FTF16450001
National Institutes of Health
Grant: 5R01-HL109711
National Institutes of Health
Grant: R01AI123001
National Institutes of Health
Grant: R01HL137562
National Institutes of Health
Grant: R01HL146267
National Institutes of Health
Grant: U01HL123336
National Institutes of Health
Grant: R01HL151283
NIA
Grant: R01 AG054366
NIAID
Grant: UM1 AI068634
NIAID
Grant: AI068634
NIAID
Grant: AI123001
AIDS Clinical Trials Group
Grant: U01 HL123339
NIAID NIH HHS
Grant: P30 AI050410
NHLBI NIH HHS
Grant: R21 HL146199
NHLBI NIH HHS
Grant: T32 HL076136
NHLBI NIH HHS
Grant: K24 HL113128
NIAID NIH HHS
Grant: UM1 AI069453
NHLBI NIH HHS
Grant: R01 HL109711
NIAID NIH HHS
Grant: U01 AI068634
NIAID NIH HHS
Grant: UM1 AI069463
NIAID NIH HHS
Grant: UM1 AI069399
Columbia University
Gilead, Janssen, Merck Sharp and Dohme
Gilead, and ViiV
Kowa Pharmaceuticals
American College of Cardiology
Gilead and ViiV Healthcare
Gilead, Merck, Emergent Biosolutions, Glaxo-Smith-Kline, Janssen, Atea, Frontier Technology, Pfizer, Viiv Healthcare, and Regeneron
Amarin, Amgen, Astra Zeneca, BI, CSL, Esperion, Janssen, Lilly, Sanofi, Regeneron, NovoNordisk, Novartis, The Medicines Company, New Amsterdam, Cerner, 89Bio, and Pfizer
REPRIEVE-EU
Gilead, ViiV Healthcare, and GSK
Infectious Disease Society of America
REPRIEVE DCC
Statistical and Data Management Center
Amarin, BMS, Esperion, Amgen, Sanofi, Regeneron, and Janssen
KOWA
Kowa Pharmaceuticals America, Gilead Sciences, and ViiV Healthcare
Amgen, Cytodyn, ViiV Healthcare, Merck, Janssen, and Pfizer
Merck, ViiV Healthcare, and Theratechnologies
ViiV Healthcare and Theratechnologies
FWCI
6.55
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals